This is a 50 site initiative to acquire a generallyâ€“accessible data repository that describes longitudinal changes in brain structure and metabolism. The goals are to acquire clinical cognitive and biomarker data for validation of imaging surrogates and to develop methods that will provide maximum power to determine treatment effects in trial involving these patients. The development of suitable biomarkers that track the progression of AD that reflect change in underlying pathology has two advantages: 1) they have greater statistical power to detect treatment effects, and 2) they provide measurements that may directly (e.g. changes in brain size, measurements of CSF proteins) indicate the rate of disease progression. The use of such biomarkers could markedly speed drug development by providing an earlier signal of drug efficacy. This is a non-treatment study of 800 subjects (200 normal controls, 400 individuals with MCI, and 200 subjects with mild AD) who will be recruited from the United States and Canada and who will be evaluated every 6 to 12 months for up to 3 years. MRI, PET, and lumbar puncture are optional procedures in this study.
July 2005 to June 2010
This project led by: Sterling Johnson, PhD